Chronic stress is increasingly recognized as a significant factor in oncology, extending from the moment of diagnosis through treatment and survivorship. A recent systematic review published in the International Journal of Molecular Sciences highlights the complex biological and clinical interactions between sustained stress and cancer progression. Drawing on evidence from breast, prostate, pancreatic, and ovarian cancers, the review emphasizes that stress is not merely an emotional experience but a physiological state capable of influencing disease pathways, treatment response, and overall quality of life.
Chronic stress is characterized by prolonged activation of the body’s stress-response systems, particularly the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Continuous stimulation of these pathways leads to elevated levels of cortisol, adrenaline, and noradrenaline, maintaining the body in a persistent “fight-or-flight” state. This sustained hormonal activation places strain on multiple organ systems, contributing to increased inflammatory signaling while simultaneously suppressing immune defenses. Such systemic alterations create biological conditions that may support tumor growth and reduce the effectiveness of anticancer therapies.
Immune dysregulation emerges as a central mechanism linking chronic stress to cancer progression. Persistent exposure to stress hormones weakens immune surveillance, impairing the body’s ability to identify and eliminate malignant cells. Chronic low-grade inflammation becomes established, favoring an environment conducive to cancer cell survival, proliferation, and evasion of normal regulatory controls. Elevated levels of inflammatory mediators such as interleukin-6 are frequently observed, particularly in more aggressive malignancies. At the tissue level, these biological changes are associated with enhanced angiogenesis, increased tumor cell migration, and the development of resistance to treatment, although isolating the direct contribution of stress remains challenging due to overlapping clinical variables.
The impact of stress varies across cancer types and prognostic groups. In malignancies with relatively higher survival rates, such as breast and prostate cancer, stress tends to be prolonged and linked to uncertainty, fear of recurrence, and long-term lifestyle adjustments. In these contexts, adrenergic and glucocorticoid signaling pathways may exert subtle but sustained influences on disease progression and therapeutic outcomes. In contrast, cancers with poorer prognoses, including pancreatic and ovarian cancers, are often associated with more severe psychological distress and depressive symptoms. Such symptoms may precede diagnosis in some cases, suggesting the possibility of underlying biological mechanisms rather than purely emotional responses.
Psychological interventions have demonstrated measurable benefits that extend beyond emotional support. Reductions in anxiety and depression, improvements in quality of life, and modulation of biological markers such as cortisol and inflammatory cytokines have been consistently reported. These findings indicate that stress-targeted interventions can influence both psychological and physiological domains. However, current evidence does not establish a direct causal relationship between stress reduction and improved survival outcomes, and the benefits of such interventions may diminish after discontinuation, highlighting the importance of sustained and integrated supportive care.
The findings support the recognition of chronic stress as a measurable clinical factor with tangible biological effects. Similar to pain, nutritional status, and sleep disturbances, stress warrants systematic assessment and management within comprehensive cancer care. Integrating psychological support, routine monitoring, and multidisciplinary approaches may not only improve patient well-being but also potentially influence disease trajectories, reinforcing the need for a more holistic approach to oncology.
Reference
- Herbetko K, Kaczor J, Sołtyk A, Kisielewska M, Opęchowski M, Sztuder A et al. The Impact of Chronic Stress on Treatment Outcomes of Cancer Patients with Divergent Survival Rates: A Systematic Review. Int J Mol Sci. 2026 Jan 9;27(2):686.